Teva Pharmaceutical Reports $4.142 Billion Revenue with Significant Operating Loss in Q2 2026

Teva Pharmaceutical Industries Ltd. reported a net revenue of $4.142 billion for the second quarter of 2026, reflecting a 1% decrease compared to $4.176 billion in the same period of 2025. The decline was primarily attributed to lower revenues from generic products, particularly lenalidomide capsules, which were partially offset by increased sales of innovative products such as AUSTEDO and AJOVY. The company's gross profit for the quarter was $2.153 billion, resulting in a gross profit margin of 52.0%, up from 50.3% in the prior year.

In terms of profitability, Teva experienced a significant operating loss of $231 million in the second quarter of 2026, a stark contrast to the operating income of $455 million reported in the same quarter of 2025. This shift was largely due to a substantial increase in research and development (R&D) expenses, which rose to $970 million, primarily driven by the acquisition of Emalex Biosciences and its asset ecopipam. The net loss attributable to Teva for the quarter was $576 million, compared to a net income of $282 million in the previous year.

Teva's strategic developments included the completion of the acquisition of Emalex Biosciences in June 2026 for approximately $700 million, with potential additional milestone payments. The company also submitted a New Drug Application (NDA) for ecopipam to the FDA, which is aimed at treating Tourette syndrome in pediatric patients. Furthermore, Teva's "Pivot to Growth" strategy, initiated in May 2023, continues to focus on enhancing its innovative product pipeline and optimizing operational efficiencies.

Operationally, Teva's U.S. segment generated revenues of $1.702 billion, down 5% year-over-year, while the Europe segment reported revenues of $1.263 billion, a decrease of 3%. In contrast, the International Markets segment saw an 11% increase in revenues to $550 million. The company’s total employee headcount and customer engagement metrics were not disclosed in the filing, but Teva continues to manage its global operations amid ongoing geopolitical challenges, particularly in regions affected by conflict.

Looking ahead, Teva anticipates continued challenges in the market, including the impact of global economic conditions and regulatory changes. The company remains focused on executing its growth strategy while managing its substantial debt, which stood at $16.593 billion as of June 30, 2026. Teva's management expressed optimism about future product launches and the potential for revenue growth from its innovative pipeline, despite the current financial setbacks.